Copper-binding peptide · extracellular matrix

GHK-Cu

Copper complex of glycyl-L-histidyl-L-lysine, widely studied in cell, skin and wound-healing models.

Evidence tier: preclinicalLiterature reviewed 2026-08-30

Mechanism & research rationale

GHK binds copper(II) and has been investigated for effects on extracellular-matrix turnover, collagen and glycosaminoglycan synthesis, metalloproteinase regulation, fibroblast activity, oxidative stress and wound-related signalling.

Human evidence

Some cosmetic and topical literature reports changes in skin appearance or matrix markers, but modern reviews highlight a surprising shortage of rigorous clinical studies and unanswered questions around skin permeability and formulation. Recent sports-medicine reviews find no convincing clinical evidence for injectable musculoskeletal use.

Preclinical / translational evidence

Cell and animal work is extensive relative to human trials and includes wound-healing, fibroblast, collagen, inflammatory and tissue-remodelling models. This supports biological plausibility but not broad clinical claims.

Key limitations

Evidence maturity: rich mechanistic/preclinical literature, limited rigorous human translation.

Selected sources

↗ GHK as a modulator of cellular pathways in skin regeneration↗ 2025 review — Topically applied GHK as an anti-wrinkle peptide↗ 2026 scoping review of emerging peptides in sports medicine
Research-use-only information. No page on this site provides medical advice, treatment recommendations or human dosing guidance.